Gompertz law based biological age (GOLD BioAge): a simple and practical measurement of biological aging to capture morbidity and mortality risks

Meng Hao,Hui Zhang,Jingyi Wu,Xiangnan Li,Yaqi Huang,MeiJia Wang,Shuming Wang,Jiaofeng Wang,Jie Chen,Zhijun Bao,Li Jin,Xiaofeng Wang,Zixin Hu,Shuai Jiang,Yi Li
DOI: https://doi.org/10.1101/2024.11.14.24317305
2024-11-15
Abstract:Biological age reflects actual aging and overall health, but current aging clocks are often complex and difficult to interpret, limiting their clinical application. In this study, we introduced a Gompertz law-based biological age (GOLD BioAge) model that simplified aging assessment. We estimated GOLD BioAge using clinical biomarkers and found significant associations of the difference from chronological age (BioAgeDiff) with risks of morbidity and mortality in NHANES. Moreover, we developed GOLD ProtAge and MetAge using proteomics and metabolomics data, which outperformed the clinical-only model in predicting mortality and chronic disease risks in UK Biobank. Benchmark analysis illustrated that our models exceeded common aging clocks in predicting mortality across diverse age groups in both NHANES and UK Biobank. The results demonstrated that the GOLD BioAge algorithm effectively applied to both clinical and omics data, showing excellent performance in predicting age-related outcomes. Additionally, we created a simplified version called the Light BioAge, which used three biomarkers for aging assessment. The Light model reliably captured mortality risks in three validation cohorts (CHARLS, RuLAS, CLHLS). It significantly predicted the onset of frailty, stratified frail individuals, and collectively identified individuals at high risk of mortality. In summary, the algorithm of GOLD BioAge could provide a valuable framework for aging assessment in public health and clinical practice.
Public and Global Health
What problem does this paper attempt to address?
The problem that this paper attempts to solve is how to construct a simple and practical biological age measurement method to more accurately capture the physiological aging state of individuals, thereby predicting disease risk and mortality. Specifically, the paper proposes the Gompertz - based Law of Biological Age (GOLD BioAge) model, aiming to simplify aging assessment through clinical biomarkers and be able to significantly correlate the difference between biological age and chronological age (BioAgeDiff) with disease incidence and mortality risk. In addition, the study also developed the ProtAge and MetAge models based on proteomics and metabolomics data. These models are superior to models using only clinical data in predicting mortality and chronic disease risk. To improve the simplicity and practicality of clinical applications, the study also created a simplified Light BioAge model, which uses only three biomarkers for aging assessment. This model has verified its effectiveness in predicting mortality in multiple independent cohorts and can significantly predict the occurrence and development of frailty states and identify individuals at high risk of death.